Prognostic factors in chronic lymphocytic leukemia

Neil Elliot Kay, Tait D. Shanafelt

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Chronic lymphocytic leukemia (CLL) is truly a heterogeneous disease, in which individual outcomes range from no need for therapeutic intervention to very aggressive, nonresponding disease. The ability to develop clear, sound prognostic information that permits reliable counsel must be our goal. A combination of easily obtainable, traditional prognostic parameters (bone marrow infiltration patterns, β-2 microglobulin) along with the clinical Rai stage is still frequently used in the initial risk stratification of patients with CLL. However, novel parameters such as defects detectable on fluorescence in situ hybridization (FISH), expression levels of CD38 and ZAP-70, and immunoglobulin heavy-chain variable region status can add significant prognostic information about a given patient with CLL. How to incorporate these newer tests within the context of the more traditional parameters for a patient with a new diagnosis is the focus of significant continuing research. The outcome of this research has implications for predicting clinical progression rates and the response and duration of response to therapy, as well as for highlighting high-risk patients who will need earlier or more specific treatment approaches.

Original languageEnglish (US)
Pages (from-to)49-55
Number of pages7
JournalCurrent Hematologic Malignancy Reports
Volume2
Issue number1
DOIs
StatePublished - Jan 2007

Fingerprint

B-Cell Chronic Lymphocytic Leukemia
Immunoglobulin Heavy Chains
Fluorescence In Situ Hybridization
Therapeutics
Bone Marrow
Outcome Assessment (Health Care)
Research

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Prognostic factors in chronic lymphocytic leukemia. / Kay, Neil Elliot; Shanafelt, Tait D.

In: Current Hematologic Malignancy Reports, Vol. 2, No. 1, 01.2007, p. 49-55.

Research output: Contribution to journalArticle

@article{d80c8f26082c41c295479e300e7c2590,
title = "Prognostic factors in chronic lymphocytic leukemia",
abstract = "Chronic lymphocytic leukemia (CLL) is truly a heterogeneous disease, in which individual outcomes range from no need for therapeutic intervention to very aggressive, nonresponding disease. The ability to develop clear, sound prognostic information that permits reliable counsel must be our goal. A combination of easily obtainable, traditional prognostic parameters (bone marrow infiltration patterns, β-2 microglobulin) along with the clinical Rai stage is still frequently used in the initial risk stratification of patients with CLL. However, novel parameters such as defects detectable on fluorescence in situ hybridization (FISH), expression levels of CD38 and ZAP-70, and immunoglobulin heavy-chain variable region status can add significant prognostic information about a given patient with CLL. How to incorporate these newer tests within the context of the more traditional parameters for a patient with a new diagnosis is the focus of significant continuing research. The outcome of this research has implications for predicting clinical progression rates and the response and duration of response to therapy, as well as for highlighting high-risk patients who will need earlier or more specific treatment approaches.",
author = "Kay, {Neil Elliot} and Shanafelt, {Tait D.}",
year = "2007",
month = "1",
doi = "10.1007/s11899-007-0007-1",
language = "English (US)",
volume = "2",
pages = "49--55",
journal = "Current Hematologic Malignancy Reports",
issn = "1558-8211",
publisher = "Springer Science + Business Media",
number = "1",

}

TY - JOUR

T1 - Prognostic factors in chronic lymphocytic leukemia

AU - Kay, Neil Elliot

AU - Shanafelt, Tait D.

PY - 2007/1

Y1 - 2007/1

N2 - Chronic lymphocytic leukemia (CLL) is truly a heterogeneous disease, in which individual outcomes range from no need for therapeutic intervention to very aggressive, nonresponding disease. The ability to develop clear, sound prognostic information that permits reliable counsel must be our goal. A combination of easily obtainable, traditional prognostic parameters (bone marrow infiltration patterns, β-2 microglobulin) along with the clinical Rai stage is still frequently used in the initial risk stratification of patients with CLL. However, novel parameters such as defects detectable on fluorescence in situ hybridization (FISH), expression levels of CD38 and ZAP-70, and immunoglobulin heavy-chain variable region status can add significant prognostic information about a given patient with CLL. How to incorporate these newer tests within the context of the more traditional parameters for a patient with a new diagnosis is the focus of significant continuing research. The outcome of this research has implications for predicting clinical progression rates and the response and duration of response to therapy, as well as for highlighting high-risk patients who will need earlier or more specific treatment approaches.

AB - Chronic lymphocytic leukemia (CLL) is truly a heterogeneous disease, in which individual outcomes range from no need for therapeutic intervention to very aggressive, nonresponding disease. The ability to develop clear, sound prognostic information that permits reliable counsel must be our goal. A combination of easily obtainable, traditional prognostic parameters (bone marrow infiltration patterns, β-2 microglobulin) along with the clinical Rai stage is still frequently used in the initial risk stratification of patients with CLL. However, novel parameters such as defects detectable on fluorescence in situ hybridization (FISH), expression levels of CD38 and ZAP-70, and immunoglobulin heavy-chain variable region status can add significant prognostic information about a given patient with CLL. How to incorporate these newer tests within the context of the more traditional parameters for a patient with a new diagnosis is the focus of significant continuing research. The outcome of this research has implications for predicting clinical progression rates and the response and duration of response to therapy, as well as for highlighting high-risk patients who will need earlier or more specific treatment approaches.

UR - http://www.scopus.com/inward/record.url?scp=34250755333&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34250755333&partnerID=8YFLogxK

U2 - 10.1007/s11899-007-0007-1

DO - 10.1007/s11899-007-0007-1

M3 - Article

VL - 2

SP - 49

EP - 55

JO - Current Hematologic Malignancy Reports

JF - Current Hematologic Malignancy Reports

SN - 1558-8211

IS - 1

ER -